Full Dose MDMA

Phase 3Small molecule

VVA Office of Research and Development

Full Dose MDMA is one of 26 small molecule programs targeting Alcohol Use Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol Use DisorderNot yet recruiting

Alcohol Use DisorderPhase 3

Not yet recruiting

Competition

Competitive Landscape

26 competitors in Alcohol Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Approved

6 2

Antabuse

Teva

Approved

2 3

Ozempic

Novo Nordisk

Phase 3

4 4

Psilocybin

COMPASS Pathways

Phase 3

8 5

Aldactone

Pfizer

Phase 2

2 6

Mounjaro

Eli Lilly

Phase 2

1 7

Minipress

Pfizer

Phase 2

1 8

LY3537031

Eli Lilly

Phase 3

2 9

Ketalar

AAultman Health Foundation

Phase 2

6 10

Naltrexone Pill

YYale University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2/3Not yet recruiting

Alcohol Use Disorder

NCT07118839

Clinical

Trials by Indication[1]

Alcohol Use Disorder1 trial

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

Not yet recruiting·VVA Office of Research and Development·Phase 2/3·NCT07118839·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Full Dose MDMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Full Dose MDMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Full Dose MDMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVA Office of Research and Development

Full Dose MDMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News